GSK Reorganized R&D Structure Will Highlight Late-Stage Development
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm plans to move eight agents into Phase III clinical trials in 2006.
You may also be interested in...
GSK Topical Antibiotic Altabax “Approvable” For Traumatic Lesions
Firm expects a decision in second quarter on a separate impetigo claim.
GSK Topical Antibiotic Altabax “Approvable” For Traumatic Lesions
Firm expects a decision in second quarter on a separate impetigo claim.
GSK Halts Development Of Vertex’ Brecanavir Due To Formulation Concerns
The investigational protease inhibitor was in Phase II development for the treatment of HIV.